Tirapazamine

替拉扎明

Report date: 2025/03/12 15:12:43
NME

Base Information

Drug NameTirapazamine
Drug Alias NametirapazaminaTirazonetirapazaminumTATENSC-130181 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[19] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSri InternationalStanford Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesTeclison LtdHangzhou Taibo Pharmaceutical Co LtdRaygene Inc +[5] 
Inactive CompaniesStanford UniversitySanofiNational Cancer Institute +[4] 
Active IndicationsUterine Cervical NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[9] 
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG